Author Archives: yaoyan 姚艳

In recent years, nanobodies (single-domain antibodies, VHHs) have rapidly emerged as a hot research direction in antibody and biologics development, thanks to their unique structure and biological properties. Derived from camelids, these single-domain antibodies feature a small size, high stability, and easy engineering capabilities, making them ideal for applications in drug discovery, diagnostics, imaging, and immunotherapy.

Membrane proteins are molecules that are critically important for life, undertaking key functions such as signal transduction, material transport, and cell recognition. With the deepening of drug development and structural biology research, membrane proteins have become central targets for new drug discovery and mechanistic studies. However, due to their structural complexity and poor stability, their […]

Explore how recombinant proteins derived from human, mouse, monkey, and dog enable more accurate antigen selection, cross-species validation, and improved antibody discovery. Learn why multi-species antigens are essential for screening, affinity evaluation, and translational drug development.

The popularity of the autoimmune track is still in full swing…

Up to $13 billions! A Roundup of Major Autoimmune Transactions in the First Half of 2025.

Efforts to improve traditional ADCs have primarily focused on the three key components: the antibody, the linker, and the payload. Previously, we summarized the research progress in bispecific ADCs. Here, we further consolidate the pipeline updates of dual-payload ADCs.

At the 2025 AACR Annual Meeting, Chinese ADC drugs have emerged in various forms such as bispecific ADCs and dual-toxin ADCs, forming a unique landscape at the AACR meeting. Here, we summarize the key players and target pipelines in the bispecific ADC (BsADC) space, based on AACR data.

The 116th AACR Annual Meeting will be held from April 25 to 30, 2025, at the McCormick Place Convention Center in Chicago, USA. Among the 6,470 abstracts released for the 2025 AACR, there are 340 related to antibody-drug conjugates (ADCs), covering various types such as single-target ADCs, dual-target ADCs, and dual-payload ADCs. These involve numerous […]